Isleworth Healthcare Acquisition Corp. ndi Cytovia Holdings, Inc. lero alengeza kuti alowa mgwirizano wotsimikizika wophatikiza bizinesi. Pakutha kwa kuphatikiza uku, Isleworth idzatchedwa Cytovia Therapeutics, Inc. ("kampani yophatikizidwa") ndi katundu wake wamba ndi zilolezo zikuyembekezeka kukhalabe zolembedwa pa NASDAQ pansi pa zizindikiro za ticker INKC ndi INKCW, motero.
Kampani yophatikizidwa ipitiliza ntchito za Cytovia ndikungoyang'ana kwambiri pakupanga ndi kupanga ma NK cell ndi nsanja zachitetezo cha NK.
Kampani yophatikizidwa idzatsogoleredwa ndi Dr. Daniel Teper, Co-Founder, Chairman, ndi Chief Executive Officer wa Cytovia.
"Ndife othokoza chifukwa cha thandizo lamphamvu lochokera kwa osunga ndalama omwe alipo komanso gulu la mabizinesi akale ku Isleworth. Tikuyembekeza kuti ntchitoyi ifulumizitsa kukwaniritsidwa kwa masomphenya a Cytovia kuti apititse patsogolo chithandizo cha NK kuchiza khansa,” adatero Dr. Teper. "Timalimbikitsidwa ndi zomwe tapeza posachedwa ku AACR, zomwe zimathandizira kupititsa patsogolo chitukuko cha maselo athu opangidwa ndi iPSC a NK (iNK) ndi Flex-NK™ cell engagers pochiza Hepatocellular Carcinoma."
A Bob Whitehead, CEO wa Isleworth, adati: "Isleworth idayesa makampani angapo a sayansi ya moyo ndipo idachita chidwi kwambiri ndi luso komanso ukadaulo womwe Cytovia adasonkhanitsa. Tikukhulupirira kuti Cytovia ndi imodzi mwamakampani apamwamba kwambiri, opanga ma cell othandizira omwe akukhudzidwa ndikukula kwamankhwala atsopano a khansa. Chithandizo cha ma cell mu oncology chabweretsa kale chiyembekezo kwa mamiliyoni. Njira za Cytovia zitha kupangitsa njira zofananira kukhala zosavuta 'zopanda shelufu' komanso zotsika mtengo. ”
Njira Yochiritsira ya Cytovia
Cytovia ikufuna kufulumizitsa kupezeka kwa odwala ku machiritso osinthika a maselo ndi ma immunotherapies, kuthana ndi zovuta zingapo zomwe sizinakwaniritse zosowa zachipatala mu oncology.
Kampaniyo imayang'ana kwambiri kugwiritsa ntchito chitetezo cham'thupi popanga zida zothandizira komanso zosokoneza za NK-cell ndi NK-engager antibody platforms. Mwachindunji, Cytovia ikupanga mitundu itatu ya maselo a iNK: maselo a inNK osasinthidwa, maselo a TALEN® opangidwa ndi jini a INK omwe ali ndi ntchito yabwino komanso kulimbikira, ndi maselo a TALEN® opangidwa ndi jini a inNK okhala ndi chimeric antigen receptors (CAR-iNKs) kuti apititse patsogolo chotupa chapadera. kulunjika. Ukadaulo wachiwiri wowonjezera wapangodya ndi nsanja yamtundu wina wamtundu wina wopangidwa kuti igwirizane ndi ma cell a NK polunjika pa NKp46 activating receptor pogwiritsa ntchito ukadaulo wa Flex-NK™.
Mapulatifomu awiriwa akugwiritsidwa ntchito popanga chithandizo chamankhwala kwa odwala omwe ali ndi Hepatocellular Carcinoma (HCC) ndi zotupa zolimba. Maphunziro azachipatala akuyembekezeka kuyambika kumapeto kwa 2022.
Likulu lawo ku Aventura, FL, Cytovia imagwira ntchito zama laboratories a R&D ku Natick, MA komanso malo opanga ma cell a cGMP ku Puerto Rico ndipo ali ndi mgwirizano wasayansi ndi Cellectis, CytoImmune Therapeutics, Hebrew University of Jerusalem, INSERM, New York Stem Cell Foundation, National Cancer Institute, ndi University of California San Francisco (UCSF). Cytovia Therapeutics yakhazikitsa CytoLynx Therapeutics posachedwa, mgwirizano womwe umayang'ana kwambiri kafukufuku ndi chitukuko, kupanga, ndi malonda ku Greater China ndi kupitirira apo.
Cytovia Pipeline
Cytovia ndi kampani yoyamba ya chitetezo chamthupi yomwe imatha kuphatikiza ma gene opangidwa ndi iPSC a NK Cell ndi Flex-NK™ cell engager antibody platforms kuti apange mbadwo wotsatira wa ma immunotherapies a zotupa za hematological ndi zolimba.
Mbiri ya Cytovia imaphatikizapo zolinga ndi zisonyezo zokhala ndi mbiri yowopsa.
GPC3 ndi chandamale chodalirika cha zotupa zolimba, makamaka hepatocellular carcinoma, komwe kufunikira kwachipatala kosakwaniritsidwa ndikofunikira kwambiri. Pulogalamu yotsogolera ya Cytovia ikufuna kupanga chithandizo choyambirira cha HCC cholunjika ku GPC3. Oyamba anayi omwe adzasankhidwa adzawunikidwa ngati monotherapies komanso ngati mankhwala ophatikiza. CYT-303, Cytovia's GPC3 Flex-NK™ engager, ndi anti-specific antibody yomwe imamangiriza ku maselo otupa a HCC kudzera mu GPC3 ndi ku NK ma cell kudzera NKp46 ndi CD16a. Kwa odwala omwe ali ndi chiwerengero chochepa kapena ntchito ya NK maselo, Cytovia adzayesa kuwonjezera kwa maselo a inNK, CYT-100, kuti atsegule mphamvu zonse za njirayi. Cytovia ikupanganso CYT-150, maselo a inNK osinthidwa jini, kuti apititse patsogolo kulowetsedwa kwa chotupa ndi kulimbikira kwa selo, zomwe zingathenso kuphatikizidwa ndi CYT-303. Kuphatikiza apo, CYT-503, GPC3 yolunjika ku CAR-iNK cell therapeutic, idapangidwa kuti ipititse patsogolo kulunjika kwa chotupa. Cytovia akuyembekeza kuyika ma IND a CYT-303 ndi CYT-100, kutsatiridwa ndi INDs a CYT-150 ndi CYT-503.
CD38 ndi chandamale chodziwika bwino chachipatala komanso malonda a Multiple Myeloma. Cytovia ikupanga CYT-338 ndi CYT-538 zomwe, motsatira, CD38-targeting Flex-NK™ cell engagers ndi ma cell a CAR-iNK pochiza Multiple Myeloma kwa odwala omwe alephera ma CD38 antibody therapy ndi othandizira omwe akutsata kusasitsa kwa B-cell. antigen (BCMA).
Cytovia ikupanganso EGFR CAR iNK candidate intracranial EGFR CAR iNK candidate to target all wtEGFR and EGFR vIII kuti athetse vuto lalikulu lachipatala mu kayendetsedwe ka Glioblastoma multiforme yosachiritsika.
Cytovia yakhazikitsa mgwirizano ndi mabungwe a maphunziro ndi ogwira nawo ntchito m'makampani kuphatikizapo Cellectis ya TALEN® gene-editing. TALEN® yosintha ma gene ndiukadaulo womwe udachita upainiya ndikuyendetsedwa ndi Cellectis, kampani yazachipatala ya biotechnology yomwe imagwiritsa ntchito nsanja yake yosinthira majini kuti ipange njira zopulumutsira ma cell ndi majini. Ma patent osinthidwa a TALEN® omwe amayendetsedwa ndi Cellectis m'munda wa iNK ndi CAR-iNK ali ndi chilolezo kuchokera ku Cellectis ndi Cytovia ndipo Cytovia ali ndi ufulu wachitukuko padziko lonse lapansi ndi malonda ku ma patent awa.
Miyezo Yokonzedweratu ndi Kugwiritsa Ntchito Zopeza
Zopeza kuchokera kuzinthu zachinsinsi ("PIPE"), ndalama mu akaunti ya trust ya Isleworth (net of redemptions), ndi ndalama zina zomwe zikuyembekezeka, pakuphatikizana mpaka madola miliyoni miliyoni, zitha kupatsa Cytovia ndalama mpaka 2. kwa zaka zambiri kuti apititse patsogolo ukadaulo wake wa iNK ndi Flex-NK™ cell engager technologies. Cytovia akukonzekera kuyang'ana kwambiri zochitika zingapo, kuphatikizapo:
• Kulemba ma IND awiri oyamba a Flex-NK™ CYT-303 ndi iNK CYT-100
• Kuyambitsa mayesero achipatala a Phase I/II kuti ayese CYT-303 ndi CYT-100, yekha komanso kuphatikiza, pochiza HCC.
• Kupeza ndi kuwonetsa zoyamba zachipatala za CYT-303 ndi CYT-100 mu HCC
• Kulemba ma IND a CYT-150 ndi CYT-503 ndikuyambitsa mayeso achipatala a Phase I/II
• Kupitiliza kupititsa patsogolo ukadaulo wa iNK & Flex-NK™ ndikupititsa patsogolo njira ndi anthu angapo azachipatala
